AIM Common Stock Shares Outstanding vs Non Current Assets Total Analysis

AIM Stock  USD 0.22  0.01  4.35%   
AIM ImmunoTech financial indicator trend analysis is way more than just evaluating AIM ImmunoTech prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether AIM ImmunoTech is a good investment. Please check the relationship between AIM ImmunoTech Common Stock Shares Outstanding and its Non Current Assets Total accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.

Common Stock Shares Outstanding vs Non Current Assets Total

Common Stock Shares Outstanding vs Non Current Assets Total Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of AIM ImmunoTech Common Stock Shares Outstanding account and Non Current Assets Total. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between AIM ImmunoTech's Common Stock Shares Outstanding and Non Current Assets Total is -0.22. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Non Current Assets Total in the same time period over historical financial statements of AIM ImmunoTech, assuming nothing else is changed. The correlation between historical values of AIM ImmunoTech's Common Stock Shares Outstanding and Non Current Assets Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of AIM ImmunoTech are associated (or correlated) with its Non Current Assets Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Current Assets Total has no effect on the direction of Common Stock Shares Outstanding i.e., AIM ImmunoTech's Common Stock Shares Outstanding and Non Current Assets Total go up and down completely randomly.

Correlation Coefficient

-0.22
Relationship DirectionNegative 
Relationship StrengthInsignificant

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.
Most indicators from AIM ImmunoTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into AIM ImmunoTech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.At this time, AIM ImmunoTech's Selling General Administrative is very stable compared to the past year. As of the 3rd of December 2024, Sales General And Administrative To Revenue is likely to grow to 109.87, while Issuance Of Capital Stock is likely to drop about 68.4 K.
 2021 2022 2023 2024 (projected)
Interest Expense67K478K549.7K281.1K
Research Development7.7M7.0M10.9M6.9M

AIM ImmunoTech fundamental ratios Correlations

-0.430.24-0.060.97-0.09-0.71-0.19-0.160.660.490.960.35-0.540.39-0.190.95-0.60.3-0.470.290.540.16-0.41-0.290.05
-0.43-0.34-0.08-0.43-0.120.290.29-0.31-0.14-0.15-0.44-0.320.28-0.30.29-0.430.56-0.21-0.070.11-0.42-0.580.870.080.16
0.24-0.340.730.12-0.060.220.360.19-0.290.040.28-0.28-0.17-0.290.590.26-0.04-0.210.26-0.490.710.37-0.320.240.64
-0.06-0.080.73-0.27-0.430.370.280.65-0.36-0.270.04-0.02-0.19-0.460.880.020.12-0.030.33-0.270.490.18-0.250.220.52
0.97-0.430.12-0.270.04-0.75-0.17-0.340.690.50.910.29-0.510.45-0.40.91-0.570.29-0.50.290.440.17-0.39-0.240.0
-0.09-0.12-0.06-0.430.040.350.06-0.43-0.420.6-0.3-0.670.250.1-0.39-0.3-0.09-0.67-0.05-0.540.030.510.070.170.01
-0.710.290.220.37-0.750.350.280.22-0.98-0.18-0.72-0.660.48-0.440.5-0.730.34-0.630.61-0.640.120.250.280.320.34
-0.190.290.360.28-0.170.060.28-0.31-0.27-0.16-0.13-0.67-0.3-0.870.18-0.160.53-0.490.11-0.630.150.160.10.890.84
-0.16-0.310.190.65-0.34-0.430.22-0.31-0.21-0.24-0.090.46-0.05-0.040.53-0.09-0.210.290.210.030.150.11-0.35-0.15-0.16
0.66-0.14-0.29-0.360.69-0.42-0.98-0.27-0.210.150.680.68-0.460.38-0.430.69-0.280.63-0.640.69-0.19-0.35-0.16-0.33-0.35
0.49-0.150.04-0.270.50.6-0.18-0.16-0.240.150.21-0.22-0.040.29-0.20.21-0.32-0.35-0.71-0.20.090.270.01-0.2-0.05
0.96-0.440.280.040.91-0.3-0.72-0.13-0.090.680.210.45-0.610.31-0.131.0-0.560.44-0.290.370.590.1-0.47-0.220.09
0.35-0.32-0.28-0.020.29-0.67-0.66-0.670.460.68-0.220.45-0.230.51-0.110.47-0.430.87-0.190.81-0.12-0.33-0.32-0.59-0.62
-0.540.28-0.17-0.19-0.510.250.48-0.3-0.05-0.46-0.04-0.61-0.230.190.08-0.590.44-0.290.29-0.11-0.33-0.40.39-0.44-0.22
0.39-0.3-0.29-0.460.450.1-0.44-0.87-0.040.380.290.310.510.19-0.380.33-0.570.52-0.240.63-0.06-0.12-0.1-0.82-0.7
-0.190.290.590.88-0.4-0.390.50.180.53-0.43-0.2-0.13-0.110.08-0.38-0.140.19-0.110.27-0.170.33-0.070.20.040.42
0.95-0.430.260.020.91-0.3-0.73-0.16-0.090.690.211.00.47-0.590.33-0.14-0.560.45-0.290.40.580.09-0.46-0.250.07
-0.60.56-0.040.12-0.57-0.090.340.53-0.21-0.28-0.32-0.56-0.430.44-0.570.19-0.56-0.370.16-0.29-0.42-0.460.310.310.4
0.3-0.21-0.21-0.030.29-0.67-0.63-0.490.290.63-0.350.440.87-0.290.52-0.110.45-0.37-0.140.81-0.1-0.39-0.24-0.43-0.49
-0.47-0.070.260.33-0.5-0.050.610.110.21-0.64-0.71-0.29-0.190.29-0.240.27-0.290.16-0.14-0.230.330.17-0.130.180.18
0.290.11-0.49-0.270.29-0.54-0.64-0.630.030.69-0.20.370.81-0.110.63-0.170.4-0.290.81-0.23-0.28-0.530.08-0.64-0.64
0.54-0.420.710.490.440.030.120.150.15-0.190.090.59-0.12-0.33-0.060.330.58-0.42-0.10.33-0.280.52-0.460.090.52
0.16-0.580.370.180.170.510.250.160.11-0.350.270.1-0.33-0.4-0.12-0.070.09-0.46-0.390.17-0.530.52-0.490.430.26
-0.410.87-0.32-0.25-0.390.070.280.1-0.35-0.160.01-0.47-0.320.39-0.10.2-0.460.31-0.24-0.130.08-0.46-0.49-0.04-0.06
-0.290.080.240.22-0.240.170.320.89-0.15-0.33-0.2-0.22-0.59-0.44-0.820.04-0.250.31-0.430.18-0.640.090.43-0.040.65
0.050.160.640.520.00.010.340.84-0.16-0.35-0.050.09-0.62-0.22-0.70.420.070.4-0.490.18-0.640.520.26-0.060.65
Click cells to compare fundamentals

AIM ImmunoTech Account Relationship Matchups

AIM ImmunoTech fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets13.8M20.2M64.6M40.5M19.4M29.4M
Short Long Term Debt Total6.4M2.3M149K837K718K682.1K
Other Current Liab214K672K438K806K1.8M1.3M
Total Current Liabilities1.1M1.1M673K1.4M8.7M9.1M
Total Stockholder Equity12.9M61.3M56.9M38.5M10.2M9.7M
Property Plant And Equipment Net7.3M6.7M4.2M1.0M824K782.8K
Net Debt4.9M(36.2M)(31.9M)(26.2M)(4.7M)(5.0M)
Retained Earnings(328.1M)(342.0M)(361.1M)(380.5M)(409.5M)(389.0M)
Accounts Payable472K383K198K377K6.4M6.8M
Cash1.5M38.5M32.1M27.1M5.4M10.3M
Non Current Assets Total9.8M24.3M7.5M4.2M4.8M8.5M
Cash And Short Term Investments8.8M39.0M48.3M34.2M13.1M19.4M
Common Stock Shares Outstanding3.6M31.8M47.3M48.0M48.6M51.0M
Liabilities And Stockholders Equity13.8M20.2M64.6M40.5M19.4M29.4M
Other Current Assets848K184K304K455K604K528.6K
Other Stockholder Equity340.2M402.5M417.2M418.3M419.0M251.9M
Total Liab7.3M3.3M820K2.0M9.1M9.6M
Total Current Assets10.4M40.3M50.2M36.3M14.6M20.9M
Short Term Debt252K47K37K178K446K423.7K
Intangible Assets1.2M1.5M2.0M1.9M2.3M1.3M
Non Currrent Assets Other1.4M(46.3M)1.3M1.2M1.7M1.8M
Net Receivables820K1.1M1.6M1.7M1.2M747.1K
Short Term Investments7.3M501K16.2M7.1M7.6M11.5M
Common Stock33K49K10K42K48K89.5K
Non Current Liabilities Total6.2M2.2M147K659K495K470.3K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether AIM ImmunoTech is a strong investment it is important to analyze AIM ImmunoTech's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact AIM ImmunoTech's future performance. For an informed investment choice regarding AIM Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AIM ImmunoTech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in AIM Stock, please use our How to Invest in AIM ImmunoTech guide.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM ImmunoTech. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM ImmunoTech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.47)
Revenue Per Share
0.004
Quarterly Revenue Growth
0.19
Return On Assets
(0.80)
Return On Equity
(1.55)
The market value of AIM ImmunoTech is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM ImmunoTech's value that differs from its market value or its book value, called intrinsic value, which is AIM ImmunoTech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM ImmunoTech's market value can be influenced by many factors that don't directly affect AIM ImmunoTech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM ImmunoTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM ImmunoTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM ImmunoTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.